Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Established in 1950, Taro Pharmaceutical Industries Ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO APPOINTS NEW CHIEF FINANCIAL OFFICER

Taro Appoints New Chief Financial Officer

Taro (TARO) delivered earnings and revenue surprises of -35.29% and -13.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Lags Q2 Earnings and Revenue Estimates

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR SEPTEMBER 30, 2021

Taro Provides Results for September 30, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE SECOND QUARTER RESULTS ON OCTOBER 28, 2021

Taro to Announce Second Quarter Results on October 28, 2021

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Taro Pharmaceutical (TARO) Q2 Earnings Expected to Decline

Taro (TARO) delivered earnings and revenue surprises of 29.76% and 7.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Q1 Earnings and Revenues Beat Estimates

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR QUARTER ENDED JUNE 30, 2021

Taro Provides Results for Quarter Ended June 30, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE FIRST QUARTER RESULTS ON JULY 27, 2021

Taro to Announce First Quarter Results on July 27, 2021

Taro Pharmaceutical Industries (TARO) has been struggling lately, but the selling pressure may be coming to an end soon.

Taro Pharma (TARO) Sees Hammer Chart Pattern: Time to Buy?

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER

Taro Announces Resignation of Chief Financial Officer

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2021

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Provides Results for the Year Ended March 31, 2021

Taro Provides Results for the Year Ended March 31, 2021

Taro Pharmaceutical Indus (NYSE:TARO) unveils its next round of earnings this Wednesday, May 19. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Earnings Preview for Taro Pharmaceutical Indus

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Full Year Results on May 19, 2021

Taro to Announce Full Year Results on May 19, 2021

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript

Taro (TARO) delivered earnings and revenue surprises of 53.25% and 14.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Q2 Earnings and Revenues Top Estimates

Taro (TARO) delivered earnings and revenue surprises of -34.48% and -25.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Misses Q1 Earnings and Revenue Estimates

ANI Pharma

Lannett Company

Mylan

Pfizer

Teva Pharmaceutical

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.

Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks

Value investors like companies with strong balance sheets and no debt; it means there are no worries about the company going broke or getting into serious financial trouble.

Taro Pharmaceuticals: Strong Balance Sheet and Strong Competition

Taro Pharmaceutical Industries Ltd.'s (TARO) CEO Uday Baldota on Q4 2020 Results - Earnings Call Transcript

Taro (TARO) delivered earnings and revenue surprises of -7.19% and 3.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Misses Q4 Earnings Estimates

Taro Pharmaceutical Industries Ltd (NYSE: TARO) former Vice President of Sales and Marketing Ara Aprahamian has been indicted by the Justice Department for price-fixing and bid-rigging on Tuesday, Reuters reported.

Former Taro Pharmaceutical VP Of Sales And Marketing Indicted for Price Fixing

Taro (TARO) delivered earnings and revenue surprises of 14.29% and -14.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Surpasses Q3 Earnings Estimates

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2020 Results - Earnings Call Transcript

Taro (TARO) delivered earnings and revenue surprises of -15.12% and -4.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Taro Pharmaceutical Industries Stock (TARO)